US FDA: Bayer to remove rest of Trasylol supplies
WASHINGTON, May 14 (Reuters) - Bayer AG (BAYG.DE: Quote, Profile, Research, Stock Buzz) will start removing the remaining supplies of its heart-surgery drug Trasylol from the U.S. market, the Food and Drug Administration said on Wednesday.
Access to the drug will be limited to investigational use, the FDA said in a statement. Bayer suspended sales of the medicine in November after research suggested an increased risk of death compared to other drugs used to control bleeding. (Reporting by Lisa Richwine; editing by Tim Dobbyn)
© Thomson Reuters 2008 All rights reserved
Help us advance this story. Provide relevant links or share your insights using our comment box. Please be considerate and help us by reporting any abuse you find. Reuters will delete comments that don't meet community standards.
Have a correction to this article? Email the editors
Sphere
Obama in Iraq twist